Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome

New England Journal of Medicine(2023)10.1056/nejmoa2202318Source: DataRank Database

Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome is a research paper published in New England Journal of Medicine (2023). On theSindex it has a DataRank of 0. It has been cited 79 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access79 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (26 grants)Impact (FWCI 13.87)OA: greenTopics (69)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (41)

Sarah A. Blackstone,Gwendolyn Clay ORCID,Rachael L. Philips ORCID,Brynja Matthiasardottir,Michele Nehrebecky

Live enrichment

PubMed:37256972 PMC:PMC10392571 OpenAlex:https://openalex.org/W4378801577

Collaborative Research Center

Grant: SFB1403; project number: 414786233

National Institutes of Health

Grant: 1Fi2GM137942-01

National Institutes of Health

Grant: National Human Genome Research Institute, Intramur

National Institutes of Health

Grant: National Institute of Arthritis and Musculoskeleta

National Institutes of Health

Grant: R35 GM119850

National Institutes of Health

Grant: S10 OD026929

National Institutes of Health

Grant: T32GM8806

National Institutes of Health

Grant: UH2 AI153029

National Institutes of Health

Grant: UL1TR001442

National Institutes of Health

Grant: Undiagnosed Diseases Network

Novo Nordisk Fonden

Grant: NNF20SA0066621

California Institute for Regenerative Medicine

Grant: CL1-00511

Hydrocephalus Association

Grant: HA-60832

Deutsche Forschungsgemeinschaft

Grant: 414786233

NIGMS NIH HHS

Grant: T32 GM008806

Intramural NIH HHS

Grant: ZID AR041180

NIGMS NIH HHS

Grant: FI2 GM137942

National Institutes of Health

Grant: 1T32GM008806-01

GRADUATE TRAINING PROGRAM IN BIONFORMATICS

National Institutes of Health

Grant: 5R35GM119850-04

Unraveling the mammalian secretory pathway through systems biology and algorithm development

National Institutes of Health

Grant: 5UH2AI153029-02

ImmCellFIE: producing high-resolution snapshots of the functions of immune cells

National Institutes of Health

Grant: 2UL1TR001442-06

UC San Diego Clinical and Translational Research Institute

Deutsche Forschungsgemeinschaft

Grant: unidentified

unidentified

National Institutes of Health

Grant: 1S10OD026929-01

Illumina NovaSeq 6000 Sequencing System

Scleroderma Research Foundation

American Academy of Allergy, Asthma and Immunology Foundation

Ludwig Institute for Cancer Research

FWCI

13.87

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

greenLicense: http://www.nejmgroup.org/legal/terms-of-use.htm

repositoryhttps://escholarship.org/content/qt1v6385v7/qt1v6385v7.pdf

publisherhttp://www.nejm.org/doi/pdf/10.1056/NEJMoa2202318

repositoryhttps://escholarship.org/uc/item/1v6385v7

journalhttps://doi.org/10.1056/nejmoa2202318

Fields of Study

Systemic Sclerosis and Related DiseasesInflammatory Myopathies and DermatomyositisMyeloproliferative Neoplasms: Diagnosis and Treatment

MeSH Terms

Gain of Function MutationAnti-Inflammatory AgentsAutoimmune DiseasesDermatologic AgentsNitrilesPyrazolesPyrimidinesScleroderma, SystemicMutation, MissenseSTAT4 Transcription FactorJanus Kinases

Keywords

ImmunologyRuxolitinibBiologyJanus kinaseCompound heterozygosityCancer researchMedicinePhenotypeGeneticsGeneBone marrowCytokineSystemic (mesh)Gain of Function Mutation (mesh)General & Internal Medicine (science-metrix)Clinical SciencesMutation, MissenseAnti-Inflammatory Agents61011 Medical and Health Sciences (for)Medical and Health SciencesSclerodermaAutoimmune DiseasesAnti-Inflammatory Agents (mesh)Missense (mesh)42 Health sciences (for-2020)General & Internal MedicineNitriles2.1 Biological and endogenous factorsPyrimidines (mesh)32 Biomedical and Clinical Sciences (for-2020)3202 Clinical Sciences (for-2020)Janus KinasesDermatologic Agents (mesh)Scleroderma, SystemicBiomedical and Clinical SciencesGenetics (rcdc)Nitriles (mesh)Inflammatory and immune systemHuman GenomeSystemicPyrazoles (mesh)Health sciences2.1 Biological and endogenous factors (hrcs-rac)STAT4 Transcription FactorHuman Genome (rcdc)Inflammatory and immune system (hrcs-hc)Janus Kinases (mesh)PyrimidinesGain of Function MutationMutationPyrazolesAutoimmune Diseases (mesh)Dermatologic AgentsMissense

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being